Cel­gene’s Revlim­id flops in Phase III lym­phoma study, shares slide

Shares of Cel­gene were dinged Mon­day evening af­ter the Big Biotech not­ed that its top fran­chise drug Revlim­id didn’t make the cut as a main­te­nance ther­a­py for dif­fuse large B-cell lym­phoma (DL­B­CL).

While the drug hit the pri­ma­ry end­point for pro­gres­sion-free sur­vival com­pared to a place­bo in the Phase III RE­MARC study, in­ves­ti­ga­tors at the Lym­phoma Aca­d­e­m­ic Re­search Or­ga­ni­za­tion in France say it failed to make a sig­nif­i­cant dif­fer­ence in over­all sur­vival. As a re­sult, Cel­gene says it’s drop­ping plans for a reg­u­la­to­ry fil­ing.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER